Latest news : Gamida Cell Ltd.

27/05/25	Gamida Cell Ltd. cancelled the acquisition of bluebird bio, Inc. from BlackRock, Inc., The Vanguard Group, Inc. and others.	CI
22/07/24	HOOKIPA Pharma Appoints Malte Peters CEO, Terry Coelho CFO	MT
18/06/24	Gamida Cell Names Rory Nealon as Chief Financial Officer	CI
18/06/24	Gamida Cell Names Sheila Frame as Chief Commercial Officer	CI
18/06/24	Gamida Cell Ltd. Names Joe Wiley as Chief Executive Officer	CI
18/06/24	Gamida Cell Ltd. announced that it has received $30 million in funding from Highbridge Capital Management, LLC	CI
23/05/24	Gamida Cell Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
10/04/24	Gamida Cell Ltd.(NasdaqGM:GMDA) dropped from S&P Global BMI Index	CI
05/04/24	Gamida Cell Ltd.(OTCPK:GMDA.Q) dropped from NASDAQ Composite Index	CI
28/03/24	Wall Street Set to Open Flat in Thursday Trading; Q4 US GDP Revised Up, Weekly Jobless Claims Fall	MT
28/03/24	Top Premarket Decliners	MT
27/03/24	Top Midday Decliners	MT
27/03/24	Wall Street Set to Open Higher Wednesday as Investors Eye End-of-Week Economic, Inflation Data	MT

More news

Analysts' recommendations : Gamida Cell Ltd.

29/01/24	JMP Securities Downgrades Gamida Cell to Market Perform From Market Outperform	MT
15/11/23	Piper Sandler Adjusts Gamida Cell's Price Target to $2 From $5, Maintains Overweight Rating	MT
15/11/23	HC Wainwright Adjusts Price Target on Gamida Cell to $5 From $11, Keeps Buy Rating	MT
19/05/23	JMP Securities Adjusts Price Target on Gamida Cell to $6 From $8, Keeps Market Outperform Rating	MT
16/05/23	Oppenheimer Adjusts Gamida Cell Price Target to $6 From $8, Maintains Outperform Rating	MT

More recommendations

Press Releases : Gamida Cell Ltd.

27/03/24	Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management	AQ
27/03/24	Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Update	AQ
22/03/24	Gamida Cell to Report Fourth Quarter and Full-Year 2023 Financial Results	AQ
23/02/24	Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®	AQ
29/01/24	Gamida Cell Actively Pursuing Strategic Alternatives	AQ

More press releases

Managers and Directors : Gamida Cell Ltd.

Manager	Title	Age	Since
Joe Wiley CEO	Chief Executive Officer	55	-
Heayoung Shin CTO	Chief Tech/Sci/R&D Officer	-	01/06/2021
Rory Nealon COO	Chief Operating Officer	59	24/05/2024

Director	Title	Age	Since
Joe Wiley CHM	Chairman	55	-
George Hampton BRD	Director/Board Member	56	01/04/2019

More insiders

Gamida Cell Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The Company is leveraging its nicotinamide (NAM)-based cell expansion technology toto expand multiple cell types including stem cells and natural killer (NK) cells while maintaining their original phenotype and potency. The Company's clinical pipeline products include: Omidubicel dedicated to hematologic malignancies and severe aplastic anemia; GDA-201 dedicated for treatment of non-Hodgkin Lymphoma; GDA-301, GDA-401, GDA-501 dedicated to treatment of solid tumors, GDA-601 dedicated to multiple myeloma.

Employees

147

Sector

Biotechnology & Medical Research

More about the company

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - OTC Markets 19:54:51 24/05/2024 +03			5-day change	1st Jan Change
0.0170 ^USD	+2.41%		-.--%	-

Market Cap	2.62M 2.26M 2.14M 1.94M 3.63M 250M 3.65M 25.37M 9.76M 127M 9.83M 9.62M 402M	P/E 2022	-1.04x	P/E 2023	-0.72x
Enterprise Value	39.01M 33.61M 31.82M 28.84M 54.11M 3.73B 54.39M 378M 145M 1.9B 146M 143M 5.99B	EV / Sales 2022	-	EV / Sales 2023	51,081,230x
Free-Float	89.41%	Yield 2022 *	-	Yield 2023	-

3 years	0.01	1.17
5 years	0.01	4.72
10 years	0.01	15.41

Date	Insider	Type	Main position	Quantity	% Market Cap.
1/31/24 A	Ronit Simantov	Free	Chief Technology Officer	480,319	0.3621%
1/31/24 A	Ivan Borrello	Free	Director	200,000	0.1508%
1/31/24 A	Kenneth Moch	Free	Director	200,000	0.1508%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GAMIDA CELL LTD.	+2.41%	-.--%	-.--%	-98.53%	2.62M
WUXI APPTEC CO., LTD.	-2.11%	-1.68%	+44.52%	+95.15%	66.93B
ARGENX SE	-0.23%	-4.45%	+30.39%	+73.64%	61.97B
INSMED INCORPORATED	+1.67%	+2.47%	-11.23%	+388.34%	28.27B
WUXI BIOLOGICS (CAYMAN) INC.	-1.05%	-4.43%	+30.56%	+10.07%	24.59B
BIONTECH SE	+0.34%	-6.78%	-7.27%	-17.99%	24.3B
GENMAB A/S	+0.43%	-3.37%	+14.85%	-19.29%	19.41B
PHARMAESSENTIA CORPORATION	-3.03%	-2.29%	+185.12%	+334.07%	16.77B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.94%	-4.94%	-5.29%	+495.65%	14.18B
EXELIXIS, INC.	-2.28%	-4.90%	+43.64%	+155.21%	13.91B
Average	-0.58%	-2.75%	+32.53%	+141.63%	27.03B
Weighted average by Cap.	-0.84%	-3.06%	+33.46%	+133.67%

Gamida Cell Ltd. Stock

Stocks

GMDA

IL0011552663

Biotechnology & Medical Research

Valuation : Gamida Cell Ltd.

Latest news : Gamida Cell Ltd.

Analysts' recommendations : Gamida Cell Ltd.

Press Releases : Gamida Cell Ltd.

Quotes and Performance

Price Extremes

Managers and Directors : Gamida Cell Ltd.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

	2022	2023
Net sales	-	1.78 1.54 1.46 1.32 2.47 170.44 2.49 17.29 6.65 86.71 6.7 6.55 273.99
Net income	-79.38M -68.39M -64.76M -58.69M -110M -7.58B -111M -769M -296M -3.86B -298M -292M -12.19B	-63M -54.28M -51.39M -46.58M -87.39M -6.02B -87.84M -610M -235M -3.06B -237M -231M -9.68B
Net Debt	39.31M 33.87M 32.07M 29.07M 54.53M 3.76B 54.81M 381M 146M 1.91B 148M 144M 6.04B	36.39M 31.35M 29.69M 26.91M 50.48M 3.48B 50.74M 353M 136M 1.77B 137M 134M 5.59B